SCHEMBL3915243

SCHEMBL3915243

CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2OCCC#N)c(=O)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.46
▸ MTOR P42345 2/20 0.46
▸ THRB P10828 1/20 0.46
▸ MDM2 Q00987 1/20 0.46
▸ NCOA1 Q15788 1/20 0.46
▸ NCOA3 Q9Y6Q9 1/20 0.46
▸ P2RY6 Q15077 6/20 0.41
▸ P2RY14 Q15391 2/20 0.41
▸ NT5E P21589 1/20 0.41
▸ P2RY2 P41231 3/20 0.40
▸ P2RY4 P51582 3/20 0.40
▸ MAPT P10636 1/20 0.39
▸ CDA P32320 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ GMNN O75496 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ NFKB1 P19838 1/20 0.37
▸ DNMT1 P26358 1/20 0.37
▸ THPO P40225 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13715908 1.00 LMNA (0.46) LMNAMTORTHRBMDM2NCOA1
SCHEMBL3915248 1.00 LMNA (0.46) LMNAMTORTHRBMDM2NCOA1
SCHEMBL24024879 0.94 LMNA (0.43) LMNAMTORTHRBMDM2NCOA1
SCHEMBL24024883 0.94 LMNA (0.43) LMNAMTORTHRBMDM2NCOA1
SCHEMBL24024770 0.93 LMNA (0.41) LMNAMTORTHRBMDM2NCOA1
SCHEMBL21970361 0.93 LMNA (0.41) LMNAMTORTHRBMDM2NCOA1
SCHEMBL14727467 0.93 LMNA (0.41) LMNAMTORTHRBMDM2NCOA1
SCHEMBL24024592 0.93 LMNA (0.41) LMNAMTORTHRBMDM2NCOA1
SCHEMBL15850638 0.93 LMNA (0.41) LMNAMTORTHRBMDM2NCOA1
SCHEMBL18902462 0.93 LMNA (0.41) LMNAMTORTHRBMDM2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569685-B2 Artificial RNAóS modified at the 2ó-hydroxyl group JAPAN SCIENCCE AND TECHNOLOGY AGENCY (JP) 2009-08-04 — — US claimed
US-20080021206-A1 Novel Artificial Rnaos Modified At The 2o-Hydroxyl Group JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2008-01-24 — — US claimed
EP-1726597-A1 NOVEL ARTIFICIAL RNAóS MODIFIED AT THE 2ó-HYDROXYL GROUP Japan Science and Technology Agency (JP) 2006-11-29 — — EP claimed
US-7569685-B2 Artificial RNAóS modified at the 2ó-hydroxyl group JAPAN SCIENCCE AND TECHNOLOGY AGENCY (JP) 2009-08-04 — — US disclosed
US-20080021206-A1 Novel Artificial Rnaos Modified At The 2o-Hydroxyl Group JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2008-01-24 — — US disclosed
EP-1726597-A1 NOVEL ARTIFICIAL RNAóS MODIFIED AT THE 2ó-HYDROXYL GROUP Japan Science and Technology Agency (JP) 2006-11-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021206-A1 Novel Artificial Rnaos Modified At The 2o-Hydroxyl Group FBL, NSUN2, METTL16 LMNA 567/4885MTOR 3400/4885THRB 3879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback